ESMO 2022

Consolidating data from prospective studies

My highlights of ESMO22

QoL and longterm toxicity

Roadmap for the adjuvant setting

Dose dense is better

Reduction of peripheral neuropathy with taxane therapy

Long-term data on dose density therapy in chemotherapy

Simple and cheap surgical technique may impact survival in early breast cancer

Dose-dense therapy is beneficial for all patients

Dose-dense standard of care is the optimal care

Hand cooling and compression both effective in preventing chemotherapy-induced peripheral neuropathy

Immuntherapy only for low risk patients?

DD is the champion!

Endocrine response in eBC

Chłodzenie rąk i terapia kompresyjna skutecznie obniżają ryzyko neuropatii obwodowej po leczeniu taksanami

Schéma dose-dense bénéfique pour toutes les patientes

Datele trialurilor se consolideata

I miei punti salienti di ESMO22

Il vincitore e’ il dose dense!!

Rosta i tania technika chirurgiczna może wpływać na czas przeżycia we wczesnym raku piersi

Dose-dense CT Efficacy confirmed in the Nodal+ ER+ population. Do all luminal patients benefit? What about secondary malignancies?

Unmeet needs and my wishes for 2022!

How to deal with the negative SERD data?

DATA: Still open questions on the optimal duration of extended adjuvant endocrine therapy? Greatest effect in the endocrine sensitive population. N+ higher risk. Contralateral disease with longer benefit

Tailoring Adjuvant Therapy

Status update - adjuvant IO. Are TILs prognostic?

Who needs Chemo? Who does not? Is OFS plus endocrine Therapy sufficient without prior Chemo? Response Assessment before surgery

More therapy options for patients with HR+, HER2+ disease

CDK4/6i could be an option for selected ER+/HER2+ disease

OS not significant, but re-assuring new data

Sacituzumab govitecan for everybody!

Survival benefit from SG in mBC

TROPiCS-02 highlights

ADC after ADC - is there any orientation?

Interim analysis shows promising data on Abema in the 1st Line

Update on biomarkers on ADCs of the DAISY trial

Endocrine-based therapy may prove more effective than chemo in “triple-positive” advanced breast cancer

Discontinued development

Survival benefit in endocrine sensitive patients

HER2+ and still without chemotherapy

Exciting data, but Phase 3 studies are needed

Another option for heavily pre-treated HR+ advanced breast cancer patients

The third in the bunch

VEX has no place in chemotherapy of metastatic breast cancer

New data re-inforces SG as a new option pre-treated HR+/HER2- patients

Negative and yet positive?!

SG is a novel treatment option for HR+/HER2- disease

My highlights of ESMO22

New treatment option for heavily pre-treated patients with ER+ MBC

Nuove opzioni di trattamento personalizzate per pazienti con tumore mammarioHR+/HER2+

Sacituzumab Govitecan: Un farmaco per tutte?

Nouvelle option thérapeutique pour les patientes lourdement prétraitées RH+ HER2-

TROPiCS-02 highlights

Survie globale pas encore significative statistiquement mais données rassurantes

Leczenie zaawansowanych raków „potrójnie dodatnich” oparte na hormonoterapii może okazać się bardziej skuteczne niż chemioterapia

Nouvelles données des analyses expolratoires dans l’étude DAISY

I miei punti salienti di ESMO22

Sopravvivenza globale nello studio MONARCH3

SG come nuova opzione di cura Per pazienti con tumore mammario HR+/HER2-

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd line Standard of Care? What will be the treatment sequence? A European, US and Asian Perspective

Monarch-3: strong OS Survival; DAWNA-2: PFS in line with existing CDK4/6i; monarcHER: a chemo-free treatment option

ADC efficacy in perspective: SG overall survival benefit, efficacy comparable for HER2- and HER2low. ADC sequencing could become an option. We need data for earlier settings.

CDK4/6i plus Trastuzumab – a possible chemo-free option for triple positive patients?

SERDs: equal PFS benefit vs. endocrine therapy; adjuvant data to be expected

Interim OS Data & PFS Update for Abemaciclib hint towards final consistent OS benefit. We need to focus on resistance drivers.

ADAURA Update - preventing relapse or just delaying it?

Concurrent preoperative IO/CRT in early lung cancer

Is OS really needed?

Window for treatment selection

Pollution and lung cancer - one mechanism revealed

Osimertinib stays standard adjuvant

Osimertinib - curing or delaying relapse?

Double IO + chemoradiotherapy - is it feasible in borderline resectable stage III NSCLC patients?

Liquid biopsy monitoring of EGFR-mutant lung cancer patients before and after surgery

Long term follow-up of ADAURA trial

Neoadjuvant strategies for PD-L1 < 1 %

INCREASE - to good to be true?

ADAURA revisited

Eine Plattform für "take the winner"-Strategie

Dubbele immunotherapie plus chemoradiotherapie - is het haalbaar bij patiënten met borderline resectable stadium III NSCLC?

Liquid biopsie monitoring van patiënten met een EGFR mutatie voor en na chirurgie

Osimertinib: una cura o ritarda la ripresa di malattia?

Osimertinib bleibt Standard adjuvant

Langzeitdaten ADAURA

Pollution et cancer du poumon - un mécanisme mis en évidence

ADAURA revisited

DFS matters!

Important data on borderline resectable patients

Sotorasib vs. Docetaxel in mKRAS G12C

Can IO be discontinued?

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Pneumonitis and T-DXd

Immunotherapy in unfit population? Perhaps...

HER2 - the next actionable mutation in lung cancer?

Can we finally treat poor prognostic patients with immunotherapy?

Cemiplimab beyond progression?

One more brick in the KRAS G12C wall

Is shorter immunotherapy equally effective and less physically demanding?

5-year update on 1st line chemoimmunotherapy

Preview on lung cancer highlights

Atezolizumab better than vinorelbin in reduced performance status

If you don't look, vou don't find - once you found it, you'll treat it!

New immunotherapy options for pts. ineligible to 1st line platinum therapy

A new step in treatment of KRAS G12C mutant NSCLC

Real-world data on Atezolizumab

5 years of chemoimmunotherapy: solid grounded

Duration of immunotherapy : Stop and go strategy for Nivo/Ipi

Chemoimmunotherapy - improvement of survival after 5 years

New therapy combination after progression on 1L osimertinib

Emerging IO mono options in the first line

Question about timing and duration of immunotherapy still unanswered

Sotorasib: sweet and sour results

5-year data on survival under immunotherapy

The journey at KRAS G12C continues

Induction chemoimmunotherapy in borderline resectability?

Liquid biopsy monitoring in treatment decisions

Poseidon and STK11/KEAP

DESTINY-Lung02 - better than the original?

Sotorasib - a new standard of care?

Die Reise bei KRAS G12C geht weiter

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

Pneumonitis und T-DXd

Chimio-immunothérapie - amélioration de la survie après 5 ans

Kann IO pausiert werden?

Un mattone in piu' nel muro del KRAS G12C

Resultados Agridulces de Sotorasib

5 Jahre Chemo-Immuntherapie: starker Effekt

Poseidon und STK11/KEAP

Cemiplimab beyond progression?

Sotorasib vs. Docetaxel bei mKRAS G12C

Durée de l'immunothérapie : stratégie Stop and Go pour l 'association Nivo/Ipi

5-Jahresüberleben mit Immuntherapie

Una nueva opción de tratamiento con IO en pacientes no tributarios de 1L con platino

IO-IO neoadjuvant bei PD-L1 neg.

Neue Therapiekombination in der Resistenz nach Osimertinib

Liquid Biopsy Monitoring zur Therapiesteuerung

Se non lo cerchi non lo troiv. Quando lo hai trovato, trattalo

Atezo besser als Vino bei PS2-3

Données de vie réelle avec l’atezolizumab

Kürzere Immuntherapie gleich effektiv aber weniger belastend?

Les études incontournables à l’ESMO 2022

Neue Option der IO-Therapie in der Erstlinie

Immunoterapia nella popolazione non fit: forse

Une nouvelle étape dans le traitement du CBNPC KRAS G12C muté

Kunnen we eindelijk patiënten met een slechte prognose behandelen met immunotherapie?

Novel data and long-term efficacy of chemo-IO in mNSCLC

Heterogenity in the genetic landscape - little progress in molecular alterations

New strategies in immunotherapy

A positive study! With a question mark?

Adjuvant CPI in kidney cancer – 2 phase III trials with novel insights!

Place of triplet therapy

Two negative studies question adjuvant approach in RCC

Immune-based peri-operative treatment in RCC: What went wrong?

No value of IPI/Nivo in the adjuvant setting.

New combo - triplet therapy for kidney cancer

Exciting data for high-risk patients: is this the start of a new era?

Adjuvant Immuntherapy in kidney cancer

More questions being raised

News in terms of adjuvant

Brief highlights about RCC & urothelial cancer from ESMO22

Tratamiento perioperatorio con immunoterapia en cáncer renal: Que ha fallado?

Terapia triple para cancer renales

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Inmunoterapia adyuvante en el cancer renales

Therapy combinations in RCC - what is the role of triplet therapy?

Shedding light on TKI/Checkpointinhibitor combinations

Immunomodulation in combination with checkpointinhibiton

Adjuvant immunotherapy options in RCC - what do we learn from ESMO22 data for the adjuvant setting?

Brief highlights about RCC & urothelial cancer from ESMO22

EV + Pembro with excellent response rates

EV + pembrolizumab in cisplatin-ineligible patients

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Promising data, but beware of toxicity

Adjuvant and neoadjuvant therapy approaches in urothelial cancer

Biomarker exploration in urothelial cancer - finding the right assay for the right drug!

PSA at 8-months as a biomarker

Triplet therapy with darolutamide in prostate cancer

Cabazitaxel better tolerated in elderly men

Optimizing cabazitaxel chemotherapy

Should intensification of ADT be considered in high-risk biochemically relapsed PC?

QoL data from ARASENS triplet therapy study mHRPC

Radicals - ADT & Radiotherapy

IM arbiraterone decanoate might demonstrate superior therapeutic index and tolerability

Combination of olaparib leads to promising results

Biomarker data for better patients selection

Further evaluation of PSA correlates

In older vulnerable - less is more

Genetic testing before PARP therapy is useful

Update on the PROpel study

Length of hormone therapy after radiation

ADCs - a possible therapeutic approach

IO + PARP without benefit in the allcomer situation

ADT + ENZA better choice than monotherapy

PSA efter 8 månader i PEACE-1 studien som biomarkör

Livskvalitetsuppföljning i ARASENS studien

Uppdatering i PROpel studien

Intimate partner violence in cancer patients

IAP-inhibition – comming game changer in LA-HNSCC Radiochemotherapy

Addition of CPI to Radiochemotherapy in LA-HNSCC?

New group of substances for rare diseases

TILs - Fashion is the eternal return of the old

Novel approach von Biontech towards Cancer – game changing potential?!